References
-
Baldwin AS Jr. The NF-
$\kappa$ B and I$\kappa$ B proteins: new discoveries and insights. Annu Rev Immunol. 1996. 14: 649-683. https://doi.org/10.1146/annurev.immunol.14.1.649 - Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol. 2006. 5: S113-S124.
- Bryniarski K, Maresz K, Szczepanik M, Ptak M, Ptak W. Modulation of macrophage activity by proteolytic enzymes. Differential regulation of IL-6 and reactive oxygen intermediates (ROIs) synthesis as a possible homeostatic mechanism in the control of inflammation. Inflammation 2003. 27: 333-340. https://doi.org/10.1023/B:IFLA.0000006701.52150.43
- Butchar JP, Parsa KV, Marsh CB, Tridandapani S. Negative regulators of toll-like receptor 4-mediated macrophage inflammatory response. Curr Pharm Des. 2006. 12: 4143-4153. https://doi.org/10.2174/138161206778743574
- Christie RM. Why is indigo blue? Biotech Histochem. 2007. 82: 51-56. https://doi.org/10.1080/00958970701267276
- Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol. 2004. 130: 627-635. https://doi.org/10.1007/s00432-004-0579-2
- Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009. 94: 3171-3182. https://doi.org/10.1210/jc.2008-2534
- Kim JK, Shin EK, Kang YH, Park JH. Indirubin-3'-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis. J Cell Biochem. 2011. 112:1384-1391. https://doi.org/10.1002/jcb.23055
- Laskin DL, Pendino KJ. Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol. 1995. 35: 655 -677. https://doi.org/10.1146/annurev.pa.35.040195.003255
- McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF, Wahl SM. Suppression of arthritis by an inhibitor of nitic oxide synthase. J Exp Med. 1993. 178: 749-754. https://doi.org/10.1084/jem.178.2.749
-
Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-
$\kappa$ B1 precursor protein and the activation of NF-$\kappa$ B. Cell 1994. 78: 773-785. https://doi.org/10.1016/S0092-8674(94)90482-0 -
Parameswaran N, Patial S. Tumor necrosis factor-
$\alpha$ signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010. 20: 87-103. https://doi.org/10.1615/CritRevEukarGeneExpr.v20.i2.10 - Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011. 31: 986-1000. https://doi.org/10.1161/ATVBAHA.110.207449
- Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 2007. 15: 252 -259. https://doi.org/10.1007/s10787-007-0013-x
-
Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-
$\kappa$ B. Annu Rev Cell Biol. 1994. 10: 405-455. https://doi.org/10.1146/annurev.cb.10.110194.002201 - Tizard IR. Immunology: an introduction inflammation. 2nd ed. 1986. pp. 423-441. Saunders College Publishing.
- Weisz A, Cicatiello L, Esumi H. Regulation of the mouse inducibletype nitric oxide synthase gene promoter by interferongamma, bacterical lipopolysaccharideand NG-monomethyl- L-arginene. Biochem J. 1996. 316: 209-215. https://doi.org/10.1042/bj3160209
- Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002. 43: 1763-1768. https://doi.org/10.1080/1042819021000006295